Serum B-cell activating factor in myecloperoxiase-antineutrophil cytoplasmic antibodies-associated vasculitis

American Journal of the Medical Sciences

Volumn 348, Issue 1, 2014, Pages 25-29

  Xin, Gang ^a   Chen, Min ^b   Su, Yun ^a   Xu, Li Xia ^c   Zhao, Ming Hui ^b   Li, Kang Sheng ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

ANCA associated vasculitis; BAFF; MPO ANCA

Indexed keywords

B CELL ACTIVATING FACTOR; MYELOPEROXIDASE;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CHINESE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VASCULITIS;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; B-CELL ACTIVATING FACTOR; BIOLOGICAL MARKERS; CYTOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; PEROXIDASE; VASCULITIS;

EID: 84903274799     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182a55ab6     Document Type: Article

References (28)

1. Chen M, Yu F, Zhang Y, et al. Antineutrophil cytoplasmic autoantibodyassociated vasculitis in older patients. Medicine (Baltimore) 2008;87: 203-9.
2. Chen M, Yu F, Zhang Y, et al. Clinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J 2005;81: 723-7.
3. Kallenberg CG. Pathogenesis of ANCA-associated vasculitis, an update. Clin Rev Allergy Immunol 2011;41: 224-31.
4. Cartin-Ceba R, Fervenza FC, Specks U. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Curr Opin Rheumatol 2012;24: 15-23.
5. Mecklenbrauker I, Kalled SL, Leitges M, et al. Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signalling. Nature 2004;431: 456-61.
6. Sun J, Lin Z, Feng J, et al. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. Eur J Pharmacol 2008;597: 1-5.
7. Zhao LD, Li Y, Smith MF Jr, et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010;19: 1534-49.
8. Bosello S, Youinou P, Daridon C, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008; 35: 1256-64.
9. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62: 168-71.
10. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109: 59-68.
11. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48: 3253-65.
12. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 2001;15: 289-302.
13. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58: 61-72.
14. Nagai M, Hirayama K, Ebihara I, et al. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibodyassociated renal vasculitis: association with disease activity. Nephron Clin Pract 2011;118:c339-45.
15. Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005;25: 298-302.
16. Bader L, Koldingsnes W, Nossent J. B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer. Clin Rheumatol 2010;29: 1031-5.
17. Holden NJ, Williams JM, Morgan MD, et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis 2011;70: 2229-33.
18. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37: 187-92.
19. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-8.
20. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66: 605-17.
21. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293: 2111-4.
22. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20: 441-53.
23. Craxton A, Draves KE, Gruppi A, et al. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005;202: 1363-74.
24. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050: 34-9.
25. Toubi E, Gordon S, Kessel A, et al. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006;27: 134-9.
26. Sanders JS, Huitma MG, Kallenberg CG, et al. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann Rheum Dis 2006;65: 1484-9.
27. Popa ER, Stegeman CA, Bos NA, et al. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103: 885-94.
28. Suppiah R, Robson J, Luqmani R. Outcome measures in ANCA-associated vasculitis. Rheum Dis Clin North Am 2010;36: 587-607.